- Abstract
- Core Tip
- Article Highlights
- Full Article (PDF)
- Full Article with Cover (PDF)
- Full Article (XML)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (21)
- Timeline of Article Publication (8)
- Authors Evaluation (2)
- Article Quality Tracking (0)
- Reference Citation Analysis (1)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3258)
All Articles published online
|
Publishing Process of This Article
|
Dec 15, 2023 (publication date) through Nov 28, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Li N, Zhu QX, Li GZ, Wang T, Zhou H. Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1α and inhibiting the RhoA/ROCK pathway. World J Diabetes 2023; 14(12): 1862-1876 [PMID: 38222788 DOI: 10.4239/wjd.v14.i12.1862] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v14/i12/1862.htm |
| Number | Citing Articles |
| 1 |
Ke-Xin Zhang, Cheng-Xia Kan, Fang Han, Jing-Wen Zhang, Xiao-Dong Sun. Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control. World Journal of Diabetes 2024; 15(2): 137-141 doi: 10.4239/wjd.v15.i2.137
Abstract(365) |
Core Tip(321) |
Full Article(HTML)(1476)
|
Full Article with Cover (PDF)-996K(80)
|
Full Article (Word)-280K(19)
|
Audio-7845K(3)
|
Peer-Review Report-194K(58)
|
Answering Reviewers-179K(40)
|
Full Article (PDF)-656K(181)
|
Full Article (XML)-80K(79)
|
Times Cited (0)
|
Total Visits (3791)
|
Open
|
| 2 |
Loredana N. Ionică, Adina V. Lința, Alina D. Bătrîn, Iasmina M. Hâncu, Bogdan M. Lolescu, Maria D. Dănilă, Lucian Petrescu, Ioana M. Mozoș, Adrian Sturza, Danina M. Muntean. The Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview. International Journal of Molecular Sciences 2024; 25(14): 7711 doi: 10.3390/ijms25147711
|
| 3 |
Sachin Dhiman, Sanchit Dhankhar, Anjali Garg, Manni Rohilla, Monika Saini, Thakur Gurjeet Singh, Samrat Chauhan, Samy Selim, Soad K. Al Jaouni, Sabina Yasmin, Naseem Begum, Aziza Alshahrani, Mohammad Yousuf Ansari. Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy. Heliyon 2024; 10(21): e39996 doi: 10.1016/j.heliyon.2024.e39996
|
| 4 |
Mina Y. George, Mohamed S. Dabour, Eman Rashad, Beshay N. Zordoky. Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy. Antioxidants 2024; 13(6): 671 doi: 10.3390/antiox13060671
|
| 5 |
Betul Rabia Erdogan, Ebru Arioglu-Inan. SGLT2 inhibitors: how do they affect the cardiac cells. Molecular and Cellular Biochemistry 2024; doi: 10.1007/s11010-024-05084-z
|